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Abstract
Purpose: This is the initial report on the utilization of combined photon irradiation followed by a neutron boost irradiation
for the initial management of patients with high-grade non-metastatic soft tissue sarcoma (STS). We present data on local
control, complications, disease-free survival and overall survival in patients at high risk for local relapse.
Methods and materials: Between 1/1/1995 and 10/31/02, twenty-three patients with high-grade non-metastatic soft tissue
sarcoma were referred to the Department of Radiation Oncology at the Detroit Medical Center. These patients were
referred for consultation due to surgical margin status (tumor within 3mm of surgical margin (n¼11)), or gross residual
disease (n¼12). There were 14 males and nine females whose ages ranged from 12 to 75 at the time of diagnosis (med¼44
years). The most common histology was malignant fibrous histiocytoma (n¼6), followed by liposarcoma (n¼5), synovial
sarcoma (n¼4), and angiosarcoma (n¼2). Twenty-one of 23 patients also received multi-agent multi-cyclic cyto-reductive
therapy. Treatment consisted of initial daily photon irradiation delivered either using twice daily fractions of 120 cGy
(n¼10) or once daily 200 cGy/fx (n¼13).Total photon dose was 36–39.6Gy. Neutron irradiation was initiated
immediately following the photon irradiation and consisted of fraction sizes of 1.0–1.25NGy to a total dose of 6–10NGy.
The neutrons were given once daily. Follow-up is calculated from the day of last radiation treatment.
Results: No patient has been lost to follow-up, which has ranged from 18 to 82 months (med¼36 months). To date there
have been two local relapses and three patients with distant disease development without local relapse. Each of the patients
with distant disease has died. The local failures occurred at 9 and 12 months. The 36-month local control is 91%. Thirty-
six month disease-free survival was 78%. Overall survival at 36 months was 87%. Three patients had unusual complications
consisting of delayed wound healing, and in one of these patients a fracture of the tibia has been noted.
Conclusion: The use of this unique radiation sequence post-surgically in patients at high risk for local relapse has resulted
in an exciting 36-month local control rate of 91%. The 3-year disease-free survival of 78% and overall survival rate of 87%
are exciting but need to mature. The low complication rate is similar to that reported in other large institutional series that
have not utilized neutrons. We continue to evaluate the role of combined photon and once-off neutron irradiation in the
treatment of patients with high-grade STS that are risk for local recurrence.
Introduction
The use of neutron radiotherapy in the treatment of
STS has been reported by several groups worldwide
with varied results [1–3]. Local control rates have
been reported from 18 to 90% and may have varied
due to treatment intent (initial management or at
the time of relapse), surgical margin status (gross
residual, microscopically positive residual or close
surgical margins), histopathology (high versus low
grade), and neutron beam characteristics (deeply
penetrating or superficial) [4].
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factors, certain parameters are accepted as to why
neutron beam radiotherapy may have a potential
benefit in the treatment of STS. These include the
lack of cell cycle positional effect for neutron killing,
difference in the oxygen enhancement ratios which
favors neutrons in hypoxic environments, and an
improved RBE [5]. However, these benefits to cell
kill are non-discriminating and are often enhanced in
hydrogen-rich tissues, often the same tissues that are
responsible for the origin of the STS, and can lead to
significant complications. These complications have
also been reported to be enhanced with increasing
treatment volume and daily neutron fraction size [6].
Although traditional surgical series have usually
reported the highest local control, overall and
disease-free survivals are not significantly different
from modern limb salvage series, with the major
cause of death development of distant disease sites
[7,8]. However, in reported series, patients treated
with either microscopic or gross residual disease had
a demonstrable reduction in local control. Recently
there has been renewed excitement regarding novel
systemic agents that may improve disease-free and
overall survival due to new mechanisms of action
when compared to more traditional chemotherapy
regimens [9,10].
The Detroit Medical Center has had neutron
beam capacity since 1984.The characteristics of the
neutron beam have been previously described [11].
Beginning in 1995 we instituted a policy to treat
selected patients (not eligible/willing to participate in
national protocols, not eligible for brachytherapy,
having pathological high-grade non-metastatic STS
with high risk for local failure based on post-surgical
margin status) with a combined photon/neutron
radiotherapy treatment course. We undertook this
action due to what was felt to be less than desirable
local failure rates seen in these patients, in our
institution. These patients were not considered for
re-operation since the surgery would have resulted in
dysfunctional limbs or would require amputation.
With an estimated RBE of 4.5, we were able to
achieve a combined dose approximately equivalent to
70–80Gy in 6 weeks. In addition, our initial
experience with this combination in the pre-operative
setting was very encouraging, in that we were
pathologically able to obtain 90–95% tumor necrosis
in the resected specimens.
We report on projected 36-month local
progression-free, disease-free and overall survival,
complications and also report on unusual post-
radiation imaging findings believed to be related to
the neutron boost radiotherapy.
Methods and materials
Between 1/1/1995 and 10/31/2002, 23 patients who
presented with non-metastatic high-grade soft tissue
sarcoma and were not participating in IRB approved
clinical trials nor were eligible for radiation therapy
that would have included brachytherapy, were
referred to the Department of Radiation Oncology
at the Detroit Medical Center for evaluation for
therapy that included neutron radiotherapy. All
patients signed informed consents.
There were 14 males and nine females referred for
initial radiotherapy management. Their ages ranged
from 12 to 75 years at the time of diagnosis
(med¼44 years). Each had undergone surgical
extirpation in an effort to obtain clean surgical
margins. However, 12 patients were referred with
gross residual disease and 11 were referred with
microscopically positive/close margins, which were
within 3mm of the rejected margin (Table I).
The most common histology was malignant
fibrous histiocytoma (MFH). This was followed
by liposarcoma (LP), synovial sarcoma (SS) and
angiosarcoma (AS). All pathology was reviewed
by one of the authors (DRL) and found to be
high grade. Each patient had standard metastatic
work-up pre-operatively and found to be without
evidence of distant disease. Twenty-one out of
23 received neoajsuvant chemotherapy, which
most often contained either an adraimycin- or a
gemcitabine-containing regimen.
Following surgical resection, radiotherapy was
initiated within 2 weeks until 1999 at which time,
due to three wound healing delays, we elected to
initiate treatments 4 weeks after surgery. Initial
irradiation consisted of either twice daily (n¼10)
or once daily (n¼13) photon irradiation to the
tumor bed plus a 5-cm margin. Each BID fraction
delivered 1.2Gy and had an interval of 4–6h
between fractions. Those treated once daily received
200cGy/fraction. The total dose delivered via the
photons ranged from 36 to 39.6Gy. Neutron therapy
was initiated immediately following the photon
irradiation. Each fraction was given once daily and
delivered 1.0–1.25NGy. Total neutrons delivered
ranged from 6 to 10NGy (Table II). The neutron
treatment field was the tumor bed plus 2cm. Custom
shielding was used where appropriate for both the
photon and neutron treatments. This is especially
relevant to the unique beam-shaping capacity that is
unique to our cyclotron.
Follow-up has been maintained on all patients
and is calculated from the last day of radiation
treatment. It has ranged from 18 to 82 months
Table I. Patient characteristics.
Male 14
Female 9
Age at diagnosis 12–75 years (median¼44 years)
Received multi-agent
chemotherapy
21/23
Follow-up 18–82 months (median¼36 months)
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examinations and radiographic imaging with
chest X-rays and CT/MRI imaging of the primary
site were carried out. These were reviewed at a
multidisciplinary conference held weekly.
Local relapse-free survival and overall survival
were calculated from the last day of neutron therapy.
Local relapse was described as any pathological
finding of recurrent disease in the field of photon
irradiation. The 36-month local control, disease-free
and overall survival were calculated using the
Kaplan–Meier method [13].
Results
Local control
At last follow-up there has been two local failures.
The first patient, who failed at 9 months, was treated
with microscopically positive surgical margins.
The failure occurred at the edge of the photon
field. The second patient, who failed at 12 months,
also treated with microscopic disease, failed within
the neutron field. The local progression-free survival
at 36 months is 91%.
Disease-free survival
Three patients, two with microscopic disease and
one with gross residual disease, have developed
distant failure while maintaining local control. All
distant disease was diagnosed within 18 months of
completion of the irradiation. These patients have
died of their disease. The 36-month disease-free
survival is 78%.
Overall survival
No patient has been lost to follow-up. At the time
of this report the three patients with distant
failures have died. The 36-month overall survival
is 87%.
Complications
There have been three patients who have suffered
from unusual delayed wound healing. These
patients prompted our decision to delay initiation
of irradiation from 2 to 4 weeks post-operatively.
Two of these patients also had received gemcitabine
as a radio-sensitizer during their photon irradiation.
In addition, one of the two receiving gemcitabine
also was noted to have a radiographic finding of
a tibeal fracture.
All other patients have exhibited RTOG grade I/II
skin toxicity. Four patients have also reported to have
reduced range of motion.
Radiographic follow-up
Early in our experience we noted patients, in whom
MRIs were obtained in routine post-therapy follow-
up, who had noticeable T2 signal changes often
lasting 6 months post-treatment. In the first three
patients in which this was noted biopsies were
obtained and reviewed by one of the authors
(DRL). In each case no tumor was found. There
were changes consistent with soft tissue injury with
significant cellular damage. After these initial
patients, no further biopsy evidence was attempted
unless there was clear evidence of new growth,
not just changes consistent with edema and soft
tissue injury.
Discussion
Local control is but one of the issues paramount in
the treatment of non-metastatic high-grade soft
tissue sarcoma. If in fact local control was the
overriding factor in survival, we would, to this day,
be using radical amputation as the standard of care.
However, it was reported that the high degree of local
control that these radical procedures established
did not translate into improved disease-free survival
[14,15]. This problem led to a search for ways to
reduce this problem of distant disease development,
but also to seek improved functional outcomes rather
than resort to amputative surgical interventions.
Pioneering work from several groups demonstrated
that ‘limb salvage’ therapy could be accomplished
with the combined modality therapy that is the
hallmark of modern care for STS [7,8].
Institutional series soon began to report local
control rates of 65–80% and without a loss in overall
survival when compared to the amputation series.
Herein lies the next great hurdle: how to approx-
imate the amputation series local control rates while
maintaining or improving on the recently reported
combined modality series. The systemic approaches
being investigated include the use of newer novel
systemic agent such as anti-angiogenesis and other
unique acting agents/drugs [9,10].
Table II. Tumor and treatment characteristics.
Histology
Malignant fibrous histiocytoma (MFH) 6
Liposarcoma (LP) 5
Synovial sarcoma (SS) 4
All others 8
Surgical margin
Within 3mm 11
Grossly positive 12
External photons treatment schedule
BID 10
QD 13
External photon total dose 36–39.6Gy
Neutron dose/fraction 1.0–1.25NGy
Total neutron dose 6–10NGy
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the attention of the neutron radiotherapy
community. STS are a collection of various tumors
of various cellular origins, often capable of rapid
growth and often with significant hypoxic popula-
tions. Thus STS became an obvious tumor system in
which the unique properties that neutrons possess
were thought to perhaps give an advantage over
photon irradiation.
Our reported series differs significantly from the
only other ongoing neutron-based experience in the
USA [1]. The University of Washington, Seattle,
recently updated their series of STS patients
who have received neutrons as their radiotherapy
management. They reported a projected 4-year local
relapse-free survival of 68%. Of interest is the
fact that 19 of the reported patients had photon
doses similar that those reported in our series.
Unfortunately these patients are not broken out
from the entire group for analysis to determine if
the photons conferred any local control advantage.
The major difference in the two series is the total
neutron doses delivered. In the Washington series
the median neutron dose was 18.3NGy, which is
almost double that which we delivered. Our concept
of neutron radiation is more in line with the
European neutron experience in which the neutrons
are used more as a ‘boost’ to supplement the
photon irradiation. These European centers have
reported widely varying local control rates of 18–94%
[16–18].
The use of neutrons, with its higher RBE, lack of
concern for the cell cycle position of target cells, and
disregard for the hypoxic status, while potentially
more lethal for STS cells is also capable of significant
normal tissue damage especially those which are
hydrogen rich. Our complication rate (RTOG Gr.
III/IV) of 13% is similar to that reported in most
series regardless of type of radiation used, whether it
includes external beam alone, brachytherapy or
neutrons. The University of Washington reported
that 21% of patients had serious chronic radiation-
related complications. The European series reported
significant complications in the range of 7–59%.
However, many of the lower rates for complications
came from European centers in which the neutrons
were used as a boost to supplement photon irradia-
tion [6,17,19]. Although our center and others
have reported on the increased risk of complications
based on increased neutron delivered per fraction,
the impact of aggressive surgical intervention and
chemotherapy prior to and after irradiation is very
difficult to asses [6] and may also play a significant
role in complication development.
Several series have also reported that the treatment
volume may play a role in increased complications
[1,2]. We agree that this may play an important role
in complication development and is one of the
main reasons why it was elected to use the neutrons
in a ‘boost’ environment, as a way to deliver
treatment to the site of the tumor bed with a limited
margin. What was also unique to this series was the
lack of influence that the surgical margin had on local
control. This, in addition to the lack of influence that
histological subgroup had on local control, differs
from the recently reported series by Zagars and Ballo
[20]. We, however, agree that dose equivalents above
60Gy are needed for patients with ‘dirty’ margins or
gross residual disease. This is in keeping with several
other reports of series that have suggested improved
local control with increased dose [21,22]. There
was also our theoretical advantage of overall time
reduction to 5.5–6 weeks to complete therapy in
which, using an RBE of 4.0, we were able to deliver
an equivalent dose of up to 80Gy, with no apparent
increase in complications.
The remaining focus of this report was to describe
the unusual and long-lasting signal abnormalities
that were seen in these patients on post-therapy
routine surveillance imaging of the primary area.
The finding of persistent soft tissue edema has
previously been reported for hyperfractionated
photon irradiation and for neutron irradiation;
however, as this is the first report that we can identify
of the combination of theses two modalities in
the treatment of STS, it is not surprising that it
occurred [23]. Initial concern led to a biopsy in the
first three patients in whom this finding was
apparent, all with pathological confirmation of soft
tissue injury without local tumor relapse.
Conclusion
We report on a series of 23 patients treated at the
time of initial presentation with a unique radiation
combination. Although photon irradiation followed
by daily neutron irradiation has been reported
from our institution in the management of prostate
cancer, this is the first report that we can identify
in which hyperfractionated irradiation has been used
in combination with neutrons in the treatment
of STS. This select group of patients, all with high-
grade STS and at high risk from local relapse,
have a projected local control rate at 36 months
of 91%. While encouraging, it will need further
maturation. The 3-year estimated disease-free and
overall survival of 78 and 87%, respectively, are also
encouraging but with the same concern regarding
length of follow-up.
The grade III/IV complication rate of 13% is
also acceptable but we have not had significant
complication, especially related to wound healing,
since we decided to delay initiation of irradiation
post-operatively from 2 to 4 weeks. We have also
documented long-term unusual imaging findings
of soft tissue injury most likely due to soft tissue
edema. These findings have been associated with the
treatment fields, especially the neutron portals.
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patients not eligible or refusing entry into national
protocols, and those not eligible for brachytherapy.
It has resulted in an exciting early local control
rate and promising relapse-free and overall 3-year
survival, although this enthusiasm must be tempered
with the knowledge that these data will need further
maturation. However, based on this report and
others from various neutron facilities worldwide,
we believe that a randomized trial to evaluate its
efficacy is warranted.
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